Platinum-Resistant Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions
Interventions
Gemcitabin+Bevacizumab
Sponsors
Hyogo cancer center
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Patient with platinum-free interval equal or less than 6 months Patient with histologically confirmed epithelial ovarian , primary peritoneal, or fallopian tube cancer Patient with radiologically or physically confirmed recurrent cancer Patient received equal or less than 2 regimens of chemotherapy Patient with ECOG Performance Status 0 to 2 Patient with adequate major organ function All patients gave written informed consent
Exclusion criteria
Exclusion criteria: Patient with active concurrent malignant disease Patient with previous malignant disease Patient previously recieved Gemcitabin or Bevacizumab Patient with serious medical condition Patient with uncontrolled hypertension Patient with severe proteinuria Patient with prior radiotherapy to the pelvis or abdomen Patient with a history of bowel obstruction, abdominal fistula, GI perforation, or hemoptysis Patient with massive pleural effusion or ascites
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the completion rate of three cycles of chemotherapy | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival Overall survival Response rate Dose-limiting toxicity | — |
Countries
Japan
Contacts
Public ContactAi Kogiku
Hyogo cancer center gynecologic oncology
Outcome results
None listed